|
1
|
Lymphoma Action: Lymphoplasmacytic
lymphoma and Waldenström's macroglobulinaemia. Lymphoma Action,
Bucks. 2022.https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/lymphoplasmacytic-lymphoma-and-waldenstroms-macroglobulinaemia#symptoms
|
|
2
|
Cautha S, Gupta S, Hanif A, Moirangthem V
and Jain K: Lymphoplasmacytic lymphoma with only lambda light chain
monoclonal paraprotein expression. Eur J Case Rep Intern Med.
9:0031062022.PubMed/NCBI
|
|
3
|
Quaglia FM, Rigolin GM, Saccenti E,
Negrini M, Volta E, Dabusti M, Ciccone M, Urso A, Laudisi M and
Cuneo A: Response to Ibrutinib of a refractory IgA
lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Mediterr J Hematol Infect Dis. 11:e20190572019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Callander NS, Adekola K,
Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ,
Costello C, D'Angelo C, et al: Waldenström
macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
22((1D)): e2400012024.PubMed/NCBI
|
|
5
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu L, Nwogbo OV, Medeiros LJ, Thakral B,
Li S, Xu J, You MJ, Wang W, Quesada AE, Ramos CB, et al:
Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: A study of
29 cases including cases that can mimic plasma cell neoplasms. Hum
Pathol. 130:47–57. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castillo JJ, Itchaki G, Gustine JN, Meid
K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, et
al: A matched case-control study comparing features, treatment and
outcomes between patients with non-IgM lymphoplasmacytic lymphoma
and Waldenström macroglobulinemia. Leuk Lymphoma. 61:1388–1394.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Awata-Shiraiwa M, Yokohama A, Kanai Y,
Gotoh N, Kasamatsu T, Handa H, Saitoh T, Murakami H, Hirato J,
Ikota H and Tsukamoto N: Waldenstrom macroglobulinemia and
non-IgM-type lymphoplasmacytic lymphoma are genetically similar.
Acta Haematol. 146:384–390. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu X, Li W, Deng Q, Li L, Hsi ED, Young
KH, Zhang M and Li Y: MYD88 L265P mutation in lymphoid
malignancies. Cancer Res. 78:2457–2462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Groen RAL, Schrader AMR, Kersten MJ,
Pals ST and Vermaat JSP: MYD88 in the driver's seat of B-cell
lymphomagenesis: From molecular mechanisms to clinical
implications. Haematologica. 104:2337–2348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ngo VN, Young RM, Schmitz R, Jhavar S,
Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al:
Oncogenically active MYD88 mutations in human lymphoma. Nature.
470:115–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martinez-Lopez A, Curiel-Olmo S, Mollejo
M, Cereceda L, Martinez N, Montes-Moreno S, Almaraz C, Revert JB
and Piris MA: MYD88 (L265P) somatic mutation in marginal zone
B-cell lymphoma. Am J Surg Pathol. 39:644–651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martino G, Marra A, Ascani S and
Sportoletti P: Uncommon lymphoplasmacytic lymphoma with IgA
paraproteinemia: A challenging clinical diagnosis solved by MYD88
mutation analysis. Ann Hematol. 98:1507–1508. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minzenmayer AN, Miranda RN, Powell PR and
Parekh PK: An unusual case of cutaneous Waldenström
macroglobulinemia with the MYD88 L265P mutation. J Cutan Pathol.
47:850–853. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao
Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88
L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J
Med. 367:826–833. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fernández-Rodríguez C, Bellosillo B,
García-García M, Sánchez-González B, Gimeno E, Vela MC, Serrano S,
Besses C and Salar A: MYD88 (L265P) mutation is an independent
prognostic factor for outcome in patients with diffuse large B-cell
lymphoma. Leukemia. 28:2104–2106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niu J, Ma Z, Nuerlan A, Li S, Cui W, Gao
H, Abulajiang G, Zhang W and Li X: Prognostic value of MYD88 L265P
mutation in diffuse large B cell lymphoma via droplet digital PCR.
Mol Med Rep. 22:1243–1256. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pham-Ledard A, Beylot-Barry M, Barbe C,
Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP
and Grange F: High frequency and clinical prognostic value of MYD88
L265P mutation in primary cutaneous diffuse large B-cell lymphoma,
leg-type. JAMA Dermatol. 150:1173–1179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu S, Luo H, Pan M, Palomino LA, Song X,
Wu P, Huang JM and Zhang Z: High frequency and prognostic value of
MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP
treatment. Oncol Lett. 15:1707–1715. 2018.PubMed/NCBI
|
|
20
|
Lee YS, Liu J, Fricano KA, Webb EM,
Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, et al:
Lack of a prognostic impact of the MyD88 L265P mutation for diffuse
large B cell lymphoma patients undergoing autologous stem cell
transplantation. Biol Blood Marrow Transplant. 23:2199–2204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Treon SP, Cao Y, Xu L, Yang G, Liu X and
Hunter ZR: Somatic mutations in MYD88 and CXCR4 are determinants of
clinical presentation and overall survival in Waldenstrom
macroglobulinemia. Blood. 123:2791–2796. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varettoni M, Zibellini S, Arcaini L,
Boveri E, Rattotti S, Pascutto C, Mangiacavalli S, Gotti M,
Pochintesta L, Paulli M and Cazzola M: MYD88 (L265P) mutation is an
independent risk factor for progression in patients with IgM
monoclonal gammopathy of undetermined significance. Blood.
122:2284–2285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossi D: Role of MYD88 in
lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology
Am Soc Hematol Educ Program. 2014:113–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou D, Yi S, Liu H, Li Z, Lyu R, Liu W, Ru
K, Zhang P, Chen H, Qi J, et al: Clinical and biological
characteristics of non-IgM lymphoplasmacytic lymphoma. Zhonghua Xue
Ye Xue Za Zhi. 36:493–496. 2015.(In Chinese). PubMed/NCBI
|
|
25
|
Kang J, Hong JY and Suh C: Clinical
features and survival outcomes of patients with lymphoplasmacytic
lymphoma, including non-IgM type, in Korea: A single-center
experience. Blood Res. 53:189–197. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brandefors L, Sander B, Lundqvist K and
Kimby E: Clinical characteristic and outcome of lymphoplasmacytic
lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish
lymphoma registry study. Br J Haematol. 196:1362–1368. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Helber MJ, Moore JE, Williams AM, Meacham
PJ, Rothberg PG and Zent CS: Ibrutinib therapy for
lymphoplasmacytic lymphoma. Am J Hematol. 92:E542–E544. 2017.
View Article : Google Scholar : PubMed/NCBI
|
